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Magnetic resonance spectroscopy (MRS) is an ideal tool for therapeutic monitoring in clinical trials 
although its role has not been formally examined.  An initial search for the use of MRS in a clinical 
trials database showed 488 studies; however many are ongoing and limited information is available 
about them.  Therefore, the results were cross-referenced with the scientific literature to find those 
studies that have been completed and have produced peer-reviewed publications.  This yielded 61 
studies demonstrating that MRS is actively used in clinical trials.  Its most frequent use is to study 
hepatic lipid content. This is followed by studies of skeletal muscle, using both proton and 
phosphorous MRS, and finally the brain, which surprisingly was the subject of only 15% of the total 
MRS studies found.  A review and summary of these studies is provided to better understand how 
MRS is used in clinical trials, and to assess its importance as a non-invasive and quantitative 
biomarker for disease. 
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1. INTRODUCTION  
The non-invasive and quantitative nature of magnetic resonance spectroscopy (MRS) makes it an 
excellent endpoint for use in clinical trials of drugs or other clinical interventions.  In longitudinal 
studies, MRS can be performed repeatedly with no harmful consequence to the patient or the clinical 
target, unlike biopsy or other invasive measures.   As a direct or surrogate biomarker, MRS is 
sensitive to the effects of medications that can be readily compared and correlated to other clinical 
measures.  Since the publication of Evidence-Based Medicine (EBM) meta-analyses 
1
, it is 
encouraging to see that MRS is being used in an increasing number of clinical trials.  While some 
studies remain small, there are now many more clinical trials with significant cohort sizes that meet 
EBM criteria.  The following is an overview of the use of MRS in recent clinical drug trials.  
1.1. Literature Search Criteria 
Since 2004, the International Committee of Medical Journal Editors (ICMJE) has 
required the registration of clinical trials as a condition of publication of research results.  
Also, in 2007 section 801 of the US Food and Drug Administration (FDA) has required by 
law that clinical trials of drugs be registered.  The US National Institutes of Health (NIH)-
supported ClinicalTrials.gov website is a registry where all studies can provide the necessary 
information required by ICMJE and the FDA.  This database is searchable and thus provides 
a valuable resource for mining data on the use of MRS in clinical trials.  As many of the 
studies are still in progress, few have indicated finalized results within the ClinicalTrials.gov 
database.  Furthermore as the results are not peer-reviewed, it is difficult to judge the quality 
of the studies from the limited information on the website.  Fortunately, entries in the registry 
are tied to PubMed.gov, a citations database of published peer-reviewed literature.  These 
two resources were used in combination to determine the extent of use of MRS by using 
“magnetic resonance spectroscopy” as a search term in ClinicalTrials.gov and then 
subsequently utilizing those results within PubMed by using the search terms: 
“clinicaltrials.gov[si]” and "magnetic resonance spectroscopy".  The resulting list of 
publications was reviewed to eliminate those studies that did not utilize in vivo MRS (for 
example, the use of high resolution NMR or MRS for the characterization of blood and other 
body fluids, was eliminated).  Individual studies were then further reviewed to include only 
prospective studies utilizing an intervention.   For the purposes of this review, interventions 
included both pharmaceutical and non-pharmaceutical (i.e. diet changes or exercise changes) 
interventions.  As a result, studies using MRS itself as an intervention, for example to 
determine if it provides better diagnosis, are excluded as they are described in another 
chapter [emrstm1474]. 
 
1.2. Literature Search Results 
The initial search on ClinicalTrials.gov found 488 registered studies that utilize MRS 
as part of the study description or intervention.  Of those studies, 318 (65%) were 
interventional studies as opposed to observational studies.  195 of the studies focused 
specifically on a pharmaceutical drug intervention.  This result demonstrates that there is 
substantial interesting in using MRS in clinical trials, particularly for the evaluation of 
treatment effects.  The initial PubMed search, which included the ClinicalTrial.gov results, 
yielded 96 studies.  Initial review of the study abstracts showed that 74 of those studies 
utilized in vivo MRS methods.  Of those 74 studies, 61 focused on a specific intervention as 
opposed to a cross-sectional study.  In almost all of these studies, the study design included 
controls with a placebo or equivalent existing medication.   
The majority of the clinical drug trials focused on the use of MRS in the liver, 
specifically to measure hepatic lipid content in 25 studies (41%).  The second largest group of 
studies focused on studying skeletal muscle (n = 17, 28%) using 
31
P (n = 9) and 
1
H MRS (n = 




H) methods.  The study counts of these two groups 
include four studies where both hepatic and skeletal muscle lipids were studied in the same 
patient.  The next largest group of studies focused on the brain, with 15 studies (25%) using 
multiple endpoints such as N-acetylaspartate (NAA), cholines (Cho), glutamate (Glu), γ-
aminobutyric acid (GABA), etc., and one study using 
31
P MRS to measure brain energetics.  
Similarly both 
31
P (n = 4) and 
1
H MRS (n = 3) were also used in seven cardiac interventional 
clinical trials representing 11.5% of the total studies.   Finally, one study used MRS to 
monitor abdominal and pelvic tumors 
2
.   The mean number of subjects in each study was 37, 
with a range of 7 to 154 subjects.  11 of the studies had 50 or more subjects and 65% of the 
studies showed significant differences and were therefore sufficiently powered.   
 
1.3. Use of Intrahepatic Triglyceride Content as a Drug Trial Endpoint 
Liver steatosis affects 20% of the population and is a key component of a number of 
major diseases including non-alcoholic fatty liver disease (NAFLD), the most common 
chronic liver disease, and hepatitis 
3
. Intrahepatic triglyceride (IHTG) content is also involved 
with insulin resistance and may therefore play a role in obesity and diabetes 
4
 (see also 
emrstm1470 and emrstm1436).   While liver biopsy remains the gold standard for 
measuring hepatic steatosis and fibrosis, the invasive nature of the procedure means that it 
cannot be used repeatedly in humans to demonstrate metabolic improvement following drug 
administration.  Other methods such as ultrasound and computed tomography (CT) do not 
provide accurate quantification of liver fat, and CT scans carry the additional burden of 
radiation exposure.  In contrast, MRS can readily quantify IHTG 
5
 without the need for biopsy 
or exposure to radiation.  Perhaps for those reasons, the majority of clinical trials focusing 
upon liver steatosis have utilized IHTG as a clinical endpoint. 
IHTG is measured using motion-corrected or breath-held single voxel acquisitions.  
Typically, additional frequency domain correction is applied, shifting each individual 
acquisition to align the water peaks before averaging them.  Intensities of the hepatic water 
peaks (4.7 ppm), and methylene peaks (-CH2-) from the fatty acid chains (1.3 ppm) are 
measured and corrected for spin-lattice (T1) and spin-spin (T2) relaxation, as shown in Figure 
1, and liver fat content is expressed as a ratio of the signal of the methylene group to the total 
signal of methylene plus water as percent fat by weight or volume 
6
. This method has been 
widely accepted as the most accurate in vivo assessment of liver fat content (see also 
emrstm1470, 1478), and by consensus NAFLD is defined as liver fat >5.6 mg fat per g of 
liver tissue, or 5.6% (w/w) of liver tissue weight 
6
.   
<Fig 1 near here> 
As would be expected, many of the drug trials that utilized IHTG as an endpoint 
focused on diseases such as NAFLD 
7-12
.   Several studies that examined the effect of 
pioglitazone, a thiazolidinedione that improves glucose and lipid metabolism, showed 
reductions in IHTG levels after drug administration 
7; 8; 10
.  Other studies focused on the use of 
mipomersen, an apolipoprotein synthesis inhibitor, in diseases such as hypercholesterolemia: 
these also showed reductions in hepatic lipid levels 
13; 14
.  Reduced IHTG or lack thereof has 
additionally been used to demonstrate the effectiveness of medications for insulin resistance 
8; 
15
.  Given IHTG’s important role in obesity and diabetes, it is not surprising that there have 




, and lifestyle 
changes 
23; 24
 where IHTG was used as an outcome measure.  One of the largest studies was a 
randomized controlled trial of 154 adults with NAFLD where 74 subjects underwent an 
intervention that included lifestyle modifications such as diet and exercise changes in 
conjunction with dietary and lifestyle consultations 
24
.  The primary outcome was remission 
of NAFLD after one year, as measured by reduction of IHTG levels to less than 5%.  The 
mean IHTG levels were reduced from 12.3% to 5.5% with successful resolution of NAFLD in 
64% of the patients, which was significantly greater than in controls (12.2% to 10.1% 
reduction and 20% resolution).   
 
1.4.   Use of Muscle Spectroscopy as a Drug Trial Endpoint 
1.4.1.  Skeletal Muscle Lipids.   Similar to the use of IHCL, characterization of the lipid 
composition of skeletal muscle is also of special interest because of the direct relationship of 
body fat to obesity and its role in insulin resistance (see also emrstm1431).  Intramyocellular 
triglyceride stores are utilized as a form of energy that decreases skeletal muscle glucose 
utilization, resulting in the impairment of glucose metabolism.  Previous studies have shown 
increased intramyocellular lipid (IMCL) levels with obesity and diabetes 
25
. While IMCL 
levels can be measured by biopsy or CT, these methods do not distinguish between intra- and 
extramyocellular (EMCL) lipid content, and of course they are also invasive or involve a 
radiation exposure. 
Proton MRS, in contrast, can assess IMCL and EMCL levels non-invasively by 
measuring the resonances at 1.2 and 1.35 ppm, respectively.  These peaks can be readily 
distinguished on an MRS spectrum 
26
 as shown in Figure 2.  Measurements of IMCL and 
EMCL are readily accomplished using conventional short spin-echo single voxel 
spectroscopy. However it is important that adipose tissue is excluded from the voxel volume 
and that the leg is positioned identically in each study, as EMCL signals are orientation-
dependent.  Measurements of IMCL and IHTG are often used together to monitor lipid 
composition before and after treatments such as growth hormone therapy 
27
 or dietary 
interventions 
25; 28; 29
 where reductions of IMCL and IHTG are positive clinical endpoints.   By 
themselves, IMCL endpoints have been utilized in studies examining the effect of medications 
such as simvastatin 
30
 or creatine supplements 
31
 which were shown to have little to no effect 
on IMCL levels.  However, IMCL is certainly sensitive to the effect of exercise, since IMCL 
levels decrease after exercise 
32; 33
.  In some of the published studies IMCL levels did not 
change, demonstrating a lack of efficacy of the intervention. 




P MRS of Skeletal Muscle.   
 31
P MRS is widely accepted as the “gold 
standard” method for noninvasive measurements of energy metabolism in exercising muscle 
34
 (see also emrstm1442). During exercise, consumption of adenosine triphosphate (ATP) is 
almost stoichiometrically correlated to the net hydrolysis of phosphocreatine (PCr) to 
inorganic phosphate (Pi). Thus changes in PCr peak height measure the intracellular energy 
status, while the ppm difference between Pi and PCr directly measures intracellular pH in the 
same spectrum 
35; 36
.  The dynamics of Pi/PCr have been used to evaluate mitochondrial 
respiration in skeletal muscle 
37; 38
, with the rate constant of post-exercise recovery kinetics of 





P spectra are collected with a pulse-and-acquire sequence using a single 
loop surface coil placed near the muscle of interest.  A magnetic resonance (MR)-compatible 
exercise device is used to perform an exercise within the MR scanner.  Data are collected at 
rest, during exercise, and during the recovery phase.  PCr is quantified for each time point and 
the time course during recovery is fitted with an exponential function to determine the rate 
constant, tau, which is representative of mitochondrial function.   A higher tau value indicates 
a faster recovery and better mitochondrial function, and vice versa.  Clinical trials that utilized 
31
P MRS to evaluate the effect of interventions on muscle energetics have shown that growth 
hormone therapy (tesamorelin) 
44
, SIRT1 gene activation (SRT2104) 
45
, and ischemic 
preconditioning 
46
 all improve PCr recovery rates and thus enhance mitochondrial function.  
On the other hand neoadjuvant chemotherapy reduces muscle energetics, as shown by reduced 
recovery rates 
47
.   Other studies have shown no effect on muscle metabolism by creatine 
supplements 
48; 49
, statin medications (simvastatin) 
50





1.4.3. Cardiac Spectroscopy.  Similar to the methods employed in skeletal muscle, cardiac 




P spectroscopy yielding similar biomarkers of 
myocardial triglyceride content and energetics (see emrstm1453,1488).  However, in 
31
P 
MRS, the PCr/ATP ratio is used instead of the post exercise PCr recovery used in skeletal 
muscle.  Spectroscopy in the heart is made much more challenging by its rapid movement in 
addition to breathing motion, thus requiring more sophisticated pulse sequences for 
prospective motion correction for 
1





H MRS cardiac studies have shown that myocardial lipid levels rise 
when subjects have free fatty acid levels increased by hyperinsulinemic-euglycemic clamping 
and intralipid infusion 
52
. It is therefore not surprising that a fat-reduced diet would result in 
lower myocardial triglyceride levels 
53
 although insulin sensitization by thiazolidinedione 
medication (rosiglitazone) does not have an effect 
54
.  Cardiac energetics can be improved in 
patients with heart failure using intravenous Allopurinol, a xanthine oxidase inhibitor which 
affects ATP synthesis 
55
.  Similarly perhexiline, which shifts myocardial metabolism from 
fatty acid to glucose utilization, improves cardiac energetics and exercise capacity in patients 
with hypertrophic cardiomyopathy or thickening of cardiac muscles 
56
. Low dose hormone 





1.5  Use of Neuro-spectroscopy as a Drug Trial Endpoint 
Unlike MRS in the liver or muscle which provides only one or two measures, 
1
H MRS of the 
brain is rich with a large number of different endpoints that can be used for clinical trials.  The 
most studied are: NAA which can be used to monitor neuronal health; Cho which indicates 
membrane turnover and can be used to assess tissue damage due to brain injury or cancer; 
measures of total (PCr plus unphosphorylated) creatine, Cr, which can be used as an energy 
marker although in most cases it serves as an internal reference; myo-inositol (mI) is an 
osmolyte and astrocytic marker; Glu (which is often indistinguishable from glutamine, they 
are frequently quantified jointly as Glx) is an excitatory neurotransmitter that is often 
modulated by disease and treatment; GABA is an inhibitory neurotransmitter; and finally 
glutathione (GSH) is an anti-oxidant whose levels may reflect neuro-inflammation 
58
.   Given 
the many different biological roles of these metabolites, there is an equally broad range of 
neurological diseases that can affect them. 
Starting first with brain cancer (see the description of the eTUMOR and INTERPRET 
trials in emrstm1474), MRS can also be utilized for therapeutic monitoring to determine the 
efficacy of medications.  Anti-angiogenic medications such as bevacizumab inhibit the VEGF 
pathway, resulting in reduced formation of tumor neovasculature. Ratai et al examined 
thirteen patients with recurrent histologically-proven glioblastoma multiforme that had failed 
to respond to radiotherapy, before and after administration of bevacizumab in addition to the 
conventional treatment regimen 
59
.  NAA/Cho levels increased and Cho/Cr levels decreased 
two weeks after treatment, a change that correlated with progression-free survival 6 months to 
a year later.  It is important to note that this study spanned three different sites with three 
different scanners yet was able to provide consistent results.  This is largely the benefit of a 
pre-post treatment study design wherein the subject serves as their own control, thus 
providing greater statistical power and eliminating the effects of inter-subject and inter-
institutional variations.   
The largest clinical trial that used MRS of the brain for testing drug efficacy was a 
randomized controlled clinical trial comparing memantine, an N-methyl-D-aspartate agonist 
with possible neuroprotective effects in Alzheimer’s disease (AD), with donepezil, a 
cholinesterase inhibitor that is the prevailing medication used for treating AD 
60
.  63 subjects 
were examined before and 6 months after treatment.  It was anticipated that decreased NAA 
and increased mI found in AD may be reversed or levels preserved following medication but 
both medications showed worsening of NAA levels rather than improvement.  The NAA 
levels correlated significantly with neurocognitive assessments, demonstrating that both 
methods accurately reflected the failures of the two medications.  In a smaller study (n=17) of 
subjects with mild cognitive impairment, a transitional stage to dementia, MRS was used to 
assess treatment with growth-hormone releasing hormone 
61
.  MRS was obtained at baseline, 
10 weeks, and 20 weeks into the treatment.  Their results demonstrated increased N-
acetylaspartylglutamate (NAAG) levels and decreased mI levels, indicative of a favorable 
treatment effect.  In addition, they observed increased GABA levels.  The next largest study 
also focused on cognitive impairment, induced in that case by human immunodeficiency 
virus.  A total of 62 patients were enrolled in a randomized placebo-controlled trial evaluating 
the benefits of the selegiline transdermal system which is thought to have anti-oxidant effects 
62
.  Similar to the study in AD, the treatment did not appear to have an effect on the brain 
metabolites, which was also reflected in a lack of effect on cognitive function.  
Multiple sclerosis (MS) is an inflammatory disease that results in demyelination of 
white matter axonal tracts.  Filippi et al studied the effects of the immunotherapeutic 
laquinimod in a phase III study of 27 relapsing-remitting MS patients, of whom 12 received 
laquinimod and the others a placebo.  While the MRS results were not significantly different, 
there appeared to be a trend towards increased NAA.  Unfortunately the researchers had 
utilized a long spin-echo acquisition, which did not allow the study of other biomarkers such 
as GSH.  GSH however was the focus of a study on therapy with N-acetylcysteine, a 
metabolic pre-cursor of GSH: administration resulted in increased GSH levels in 6 subjects (3 
with Parkinson’s disease and 3 with Gaucher’s disease, both of which involve oxidative 
stress) when compared to 3 controls.  This preliminary result shows that MRS is a promising 
tool for monitoring neuroinflammation. 
As systemic changes can also affect brain metabolism, MRS of the brain has been 
used for assessing the effect of treatments for diseases that originate outside of the brain.  
Hepatic encephalopathy results from liver diseases that affect the brain via circulating toxins, 
such as ammonia, resulting in increased Glx and reduced mI, Cho, and eventually NAA.  A 
study of 60 subjects with minimal hepatic encephalopathy examined the effect of lactulose, 
which reduces levels of ammonia in the body.  MRS conducted before and after 3 months of 
treatment demonstrated a positive outcome, as measured by MRS, with increases in mI and 
Cho and reductions in Glx.  Another study examined the effects of post-cancer fatigue in 39 
subjects treated with cognitive behavioral therapy: however in this case there was no effect of 
the treatment 
63
. In contrast, another smaller clinical trial utilizing cognitive behavioral 
therapy to reduce pain in fibromyalgia, a syndrome with similar symptoms to cancer fatigue, 
did show changes (reduced Glu/Cr in 10 subjects) 
64
. 
Psychiatric disorders have also utilized MRS heavily for the evaluation of drug 
efficacy.  In the majority of the studies, glutamate levels appear to be the most important 
indicators of response.   For example, acamprosate has been successfully used to treat 
alcoholism although its mechanism of action is unclear.   It is thought that it may act through 
regulation of a hyper-glutamatergic state resulting from cyclic intoxication and withdrawal.  
In one study, 33 patients undergoing alcohol withdrawal were given acamprosate or placebo 
and MRS was acquired before and after treatment 
65
.  There were significant reductions of 
brain glutamate, in those subjects given acamprosate when compared to the placebo group, 
thus supporting the hypothesis.   Similarly, ten adolescents suffering from attention deficit 
hyperactivity disorder, which also results in excess intracerebral glutamate, were given the 
stimulant methylphenidate, to determine if Glu would change 
66
.  Although significant 
differences between control and ADHD subjects were observed, the medication itself did not 
appear to alter cerebral Glu levels.   Using a more cognitive approach, and relying on 
measures of NAA and Cho rather than Glu, another study examined 8 bipolar patients before 
and after administration of galantamine, an acetylcholinesterase inhibitor, and found an 
increase in NAA and decrease in Cho, thus demonstrating changes indicative of restoration 
of cognition 
67
.  The same group utilized 
31
P MRS and found that patients (n=6) with major 
depressive disorder who responded to triiodothyronine, a thyroid hormone with 
antidepressant effects, showed significantly increased brain ATP levels compared to non-
responders (n=10) 
68
.   
Given the relative ease of acquiring spectra from the brain (with typically no need for 
motion correction, for example), it is somewhat surprising that there have been fewer clinical 
trials using MRS in the brain than in the liver and muscle.  Issues such as reproducibility and 
differences in protocols, as described earlier in this chapter, certainly play a role; however one 
of the main differences is that unlike liver and muscle spectroscopy, where the measures are 
direct assessments of lipid or energetics, neuro-spectroscopy metabolites such as NAA are 
putative and indirect markers of brain health.   The more recent studies that focused on 
neurotransmitters such as Glu and GABA are perhaps utilizing more direct measure of 
cerebral metabolism, although even here, arguably, the metabolite measurements represent 
steady-state concentrations of pools of the neurotransmitters and do not take into account the 
dynamic exchange of these metabolites.  The advent of advanced MRS methods such as 
13
C-
labelled spectroscopy and hyperpolarized MRS may help to overcome some of these barriers. 
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FIGURES AND CAPTIONS  
 
Figure 1. Measuring Lipid Content in the Liver using 
1
H MRS.  The spectrum was 
acquired from the right lobe of the liver in a healthy volunteer using breath-held single 
voxel spectroscopy (PRESS, echo-time TE=35ms, 16 averages) on at 3T MR scanner 
(Siemens Verio) using an 8 channel phased array torso surface coil.   
 
 
Figure 2. Measuring Intramyocellular Lipid in Skeletal Muscle using 
1
H MRS.  Single 
voxel spectra were acquired from the skeletal muscle of (a) a human immuno-deficiency 
virus (HIV)-positive patient suffering from lipodystrophy as compared to b) control 
with no lipodystrophy using a lower extremity transmit-receive coil at 1.5T (using a GE 
Signa scanner)
69
.  Note the increase in extramyocellular lipid (EMCL) when compared 
the intramyocellular lipids (IMCL).   
 
 
Figure 3. Dynamic 
31
P MRS of Skeletal Muscle. A stackplot of spectra acquired during 
baseline, exercise, and recovery (annotated at right) is shown.  Spectra were acquired 
using a non-localized 90
o
 pulse-and-acquire sequence (repetition period TR=2 secs, 
spectral width of 6 kHz) using a single channel 
31
P coil at 3T (Siemens Verio) from B. 
Rowland et al. 2015
70
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